logo
What is the summer solstice? What to know about the longest day of the year

What is the summer solstice? What to know about the longest day of the year

Yahoo18-06-2025
This year, the Northern Hemisphere's summer solstice occurs on June 20 at 10:42 p.m. EST. South of the Equator, this same moment marks the beginning of summer. Solstices occur at the same time around the world, but their local times vary with time zones.
Traditionally, summer and winter solstices helped mark the changing of the seasons—along with their counterparts, the spring and autumnal equinoxes.
However, today's meteorologists officially use temperature records instead to draw lines between the seasons. So what exactly are solstices—and how have they been celebrated throughout history? Here's all you need to know.
Solstices occur because Earth's axis of rotation is tilted about 23.4 degrees relative to Earth's orbit around the sun. This tilt drives our planet's seasons, as the Northern and Southern Hemispheres get unequal amounts of sunlight over the course of a year. From March to September, the Northern Hemisphere is tilted more toward the sun, driving its spring and summer. From September to March, the Northern Hemisphere is tilted away, so it feels like autumn and winter. The Southern Hemisphere's seasons are reversed.
(Here's the difference between astronomical and meteorological seasons.)
On two moments each year—what are called solstices—Earth's axis is tilted most closely toward the sun. The hemisphere tilted most toward our home star sees its longest day, while the hemisphere tilted away from the sun sees its longest night. During the Northern Hemisphere's winter solstice—which always falls around December 22—the Southern Hemisphere gets its summer solstice. During the Northern Hemisphere's summer solstice—which always falls around June 21—the Southern Hemisphere gets its winter solstice.
You can also think about solstices in terms of where on Earth the sun appears. When it's a summer solstice in the Northern Hemisphere, the sun appears directly over the Tropic of Cancer, the latitude line at 23.5 degrees North. (That's as far north as you can go and still see the sun directly overhead.) During the Northern Hemisphere's winter solstice, the sun appears directly over the Tropic of Capricorn, the Tropic of Cancer's southern mirror image.
Earth is not the only planet with solstices and equinoxes; any planet with a tilted rotational axis would see them, too. In fact, planetary scientists use solstices and equinoxes to define "seasons" for other planets in our solar system.(Here's what to know about equinoxes, too.)
It's worth noting, though, that other planets' seasons don't climatically equal those on Earth for a few reasons. First, planets vary in their axial tilts: Venus's axis of rotation is tilted by just three degrees, so there's much less seasonal difference between the Venusian summer and winter solstices than those on Earth. In addition, planets such as Mars have less circular orbits than Earth's, which means that their distances from the sun vary more dramatically than ours do, with correspondingly bigger effects on seasonal temperature.
Earth's axial tilt plays a much bigger role than its near-circular orbit in governing annual seasons. Earth makes its closest annual approach of the sun about two weeks after the December solstice, during the Northern Hemisphere's winter. Earth is farthest from the sun about two weeks after the June solstice, during the Northern Hemisphere's summer.
For millennia, cultures around the world have devised ways to celebrate and revere these celestial events—from building structures that align with the solstice to throwing raucous festivals in its honor.
(These are 6 of the best destinations to celebrate midsummer in Europe.)
Though the purpose of the enigmatic English structure Stonehenge remains unknown, this 5,000-year-old monument has a famously special relationship with the solstices. On the summer solstice, the complex's Heel Stone, which stands outside Stonehenge's main circle, lines up with the rising sun.
(Learn more about how to visit Stonehenge.)
In Egypt, the Great Pyramids at Giza appear to be aligned with the sun as well. When viewed from the Sphinx, the sun sets between the pyramids of Khufu and Khafre during the summer solstice—though it remains unclear precisely how the ancient Egyptians oriented it this way.
Many cultures have found unique ways to mark the summer solstice. The traditional Scandinavian holiday of Midsummer welcomes it with maypole dancing, drinking, and romance. During the Slavic holiday of Ivan Kupala, people wear floral wreaths and dance around bonfires, while some plucky souls jump over the fires as a way of ensuring good luck and health. In a more modern tradition, the people of Fairbanks, Alaska, swing in the summer solstice with a nighttime baseball game to celebrate the fact that they can get up to 22.5 hours of daylight in the summer. The Midnight Sun Game has been played since 1906.
(See the summer solstice from a Roman emperor's party cave.)
The winter solstice has had its share of celebrations, too. On June 24, in time with the Southern Hemisphere's winter solstice, the Inca Empire celebrated Inti Raymi, a festival that honored the Inca religion's powerful sun god Inti and marked the Inca new year. The festival is still celebrated throughout the Andes, and since 1944, a reconstruction of Inti Raymi has been staged in Cusco, Peru, less than two miles from its Inca Empire home. Ancient Romans celebrated the winter solstice with Saturnalia, a seven-day festival that involved giving presents, decorating houses with plants, and lighting candles. And Iranians celebrate Yalda in December. The festival—a mainstay since Zoroastrianism was Iran's dominant religion—traditionally honors the birth of Mithra, the ancient Persian goddess of light.
If solstices mark the brightest and darkest days of the year, why don't temperatures reflect that?
In short, it's because it takes time for Earth's land and water to heat up and cool down. In the U.S., the year's coldest temperatures set in after-mid January, roughly a month after the Northern Hemisphere's winter solstice. Likewise, thermometers hit their high in the U.S. in July and August, weeks after the summer solstice.
Some believe, too, that since Earth's rotation is slowing down, each new solstice sets a new record for daytime length. But that's not the case.
It's certainly true that Earth's rotation has slowed over billions of years, as Earth loses angular momentum to our planet's tides. Growth lines on fossil corals show that more than 400 million years ago, days on Earth lasted less than 22 hours.
But Earth's gradual slowing down isn't the only factor at play. Picture a figure skater twirling on their skates; they can speed up or slow down their twirls by how much they tuck in their limbs. In much the same way, changes in the distribution of Earth's mass—from the winds of El Niño to the melting of Greenland's ice—can subtly tweak our planet's rotation rate.
Taking all this into account, it's thought that the longest day since the 1830s occurred sometime in 1912. It lasted less than four milliseconds longer than the recent average.
This article originally published on December 19, 2022 and has been updated with new information.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Satellite tracking oil and gas emissions goes dark
Satellite tracking oil and gas emissions goes dark

E&E News

time13 minutes ago

  • E&E News

Satellite tracking oil and gas emissions goes dark

An $88 million methane-tracking satellite that attracted funding from the likes of Amazon founder Jeff Bezos and the government of New Zealand is no longer operating. Ground crews lost contact June 20 with MethaneSAT, which was launched in March 2024, the Environmental Defense Fund announced Tuesday. Officials said they recently learned that the satellite lost power and was 'likely not recoverable.' EDF said MethaneSAT was the first satellite developed by an environmental nonprofit, and the group sought to publicly distribute the methane data collected by the project. EDF began publishing some of that data last year and had partnered with Google to create a massive, global map of methane emissions from oil and gas sites. Advertisement 'While this is difficult news, it is not the end of the overall MethaneSAT effort, or of our work to slash methane emissions,' EDF officials wrote in a statement.

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome
Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Yahoo

time26 minutes ago

  • Yahoo

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

SPEAR Study Group initiated following multiple, independent reports of substantial clinical benefit associated with PEMGARDA® (pemivibart) therapy among people with Long COVID SPEAR Study Group collaborators Drs. Michael Peluso, Amy Proal, and David Putrino are key thought leaders in the clinical and translational biology of Long COVID and Post-Vaccination Syndrome Initial SPEAR clinical efforts to be aimed at rigorous, controlled assessment of monoclonal antibody safety, translational biology, and exploratory efficacy in relevant patient populations characterized by persistent virus or circulating SARS-CoV-2 spike protein WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that it has formed a best-in-class clinical and translational study group, the SPEAR Study Group, with leading investigators focused on the biology and clinical disease or injury associated with chronic exposure to SARS-CoV-2 virus or mRNA vaccine-mediated spike protein. The SPEAR Study Group will structure and guide anticipated clinical trials evaluating the effects of broadly neutralizing anti-SARS-CoV-2 spike protein monoclonal antibody (mAb) therapy in people suffering from Long COVID or Post-Vaccination Syndrome (PVS), conditions believed to be mediated by persistent viral reservoirs or circulating spike protein. Persistent SARS-CoV-2 spike protein has been identified in both populations, and both populations have overlapping manifestations of apparent clinical disease. As many as 5% or more of Americans have reported recent Long COVID symptoms, an extraordinary medical burden that will continue to evolve as infections continue in the SPEAR Study Group was initiated in response to a growing number of case reports and reported case series from across the U.S. suggesting meaningful symptom relief / remission of Long COVID following use of PEMGARDA® (pemivibart), a monoclonal antibody currently authorized by the U.S. Food and Drug Administration (FDA) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain immunocompromised individuals. PEMGARDA is not authorized for the treatment of Long COVID. While these emerging reports are anecdotal and uncontrolled, they collectively support a longstanding, mechanistically plausible hypothesis: that prolonged exposure to pathogenic SARS-CoV-2 spike protein or other forms of persistent virus or viral material may drive disease in some patients, and that reducing this burden through monoclonal antibody therapy may offer a promising therapeutic approach worthy of rigorous clinical investigation. Clinical research to be planned by the SPEAR Study Group is critical to exploring disease biology and evaluating efficacy endpoints that can enable registrational studies if appropriate in the future. The SPEAR Study Group includes the following investigators and researchers who, along with Invivyd, will collaborate on the design and anticipated execution of relevant clinical trials: Michael Peluso, M.D., MHS, Assistant Professor of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco Amy Proal, Ph.D., Co-Founder and CEO, Polybio Research Foundation and Scientific Director, Mount Sinai Cohen Center for Recovery from Complex Chronic Diseases ('CoRE') David Putrino, Ph.D., Nash Family Director of the Mount Sinai Cohen Center for Recovery from Complex Chronic Diseases ('CoRE') and Professor, Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai. The SPEAR Study Group intends to launch collaborative, multi-center translational clinical research on Long COVID, including PVS, as soon as practicable, including use of next-generation monoclonal antibody candidates from Invivyd such as VYD2311. 'It is now clear from a growing body of high-quality, peer-reviewed research that persistent spike protein or viral reservoirs can be identified in a meaningful portion of people with Long COVID,' said Dr. Peluso. 'For the first time in years, there is a company with the capability to explore this space using active, broadly neutralizing monoclonal antibodies. This research marks an essential step toward understanding what may cause debilitating COVID-driven chronic disease, and we hope will lay the groundwork for future efficacy studies that could deliver real therapeutic options to patients who have waited far too long.' 'Long COVID is a pervasive, debilitating, and underappreciated public health challenge affecting millions of adults and children in the U.S., with no approved treatments,' said Marc Elia, Chairman of the Board at Invivyd. 'Monoclonal antibodies have already demonstrated efficacy in preventing acute COVID-19 infections and treating acute COVID-19 infections, including long-term infections, and emerging anecdotal reports suggest pemivibart may have potential in addressing symptoms in some Long COVID patients. We believe that monoclonal antibodies are key to managing the ongoing burden of endemic COVID-19 disease in all forms, and as previously disclosed, we will be meeting with the FDA early in 3Q to discuss rapid approval pathways for COVID-19 mAbs. Meanwhile, our formation of the SPEAR Study Group is a critical step toward potentially unlocking a Long COVID treatment opportunity for patients in need by generating data needed to inform future studies and potential regulatory pathways. We look forward to sharing future milestones as we advance this important initiative.' About PEMGARDA PEMGARDA® (pemivibart) is a half-life extended investigational monoclonal antibody (mAb). PEMGARDA was engineered from adintrevimab, Invivyd's investigational mAb that has a robust safety data package and provided evidence of clinical efficacy in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19. PEMGARDA has demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1, KP.3.1.1, XEC and LP.8.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells. PEMGARDA (pemivibart) injection (4500 mg), for intravenous use is an investigational mAb that has not been approved, but has been authorized for emergency use by the U.S. FDA under an EUA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2. PEMGARDA is not authorized for use for treatment of COVID-19, treatment of Long COVID, or post-exposure prophylaxis of COVID-19. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccinations, should receive COVID-19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. Anaphylaxis has been observed with PEMGARDA and the PEMGARDA Fact Sheet for Healthcare Providers includes a boxed warning for anaphylaxis. The most common adverse reactions included systemic infusion-related reactions and hypersensitivity reactions, local infusion site reactions, and infusion site infiltration or extravasation. For additional information, please see the PEMGARDA full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning. To support the EUA for PEMGARDA, an immunobridging approach was used to determine if PEMGARDA may be effective for pre-exposure prophylaxis of COVID-19. Immunobridging is based on the serum virus neutralizing titer-efficacy relationships identified with other neutralizing human mAbs against SARS-CoV-2. This includes adintrevimab, the parent mAb of pemivibart, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA. Evidence of clinical efficacy for other neutralizing human mAbs against SARS-CoV-2 was based on different populations and SARS-CoV-2 variants that are no longer circulating. Further, the variability associated with cell-based EC50 value determinations, along with limitations related to pharmacokinetic data and efficacy estimates for the mAbs in prior clinical trials, impact the ability to precisely estimate protective titer ranges. Additionally, certain SARS-CoV-2 viral variants may emerge that have substantially reduced susceptibility to PEMGARDA, and PEMGARDA may not be effective at preventing COVID-19 caused by these SARS-CoV-2 viral variants. The emergency use of PEMGARDA is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner. PEMGARDA is authorized for use only when the combined national frequency of variants with substantially reduced susceptibility to PEMGARDA is less than or equal to 90%, based on available information including variant susceptibility to PEMGARDA and national variant frequencies. About VYD2311 VYD2311 is a novel monoclonal antibody (mAb) candidate being developed for COVID-19 to continue to address the urgent need for new prophylactic and therapeutic options. The pharmacokinetic profile and antiviral potency of VYD2311 may offer the ability to deliver clinically meaningful titer levels through more patient-friendly means such as an intramuscular route of administration. VYD2311 was engineered using Invivyd's proprietary integrated technology platform and is the product of serial molecular evolution designed to generate an antibody optimized for neutralizing contemporary virus lineages. VYD2311 leverages the same antibody backbone as pemivibart, Invivyd's investigational mAb granted emergency use authorization in the U.S. for the pre-exposure prophylaxis (PrEP) of symptomatic COVID-19 in certain immunocompromised patients, and adintrevimab, Invivyd's investigational mAb that has a robust safety data package and demonstrated clinically meaningful results in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19. About Invivyd Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit to learn more. Trademarks are the property of their respective owners. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'could,' 'expects,' 'estimates,' 'intends,' 'potential,' 'predicts,' 'projects,' and 'future' or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, expectations regarding the SPEAR Study Group and its anticipated goals; the plans of the SPEAR Study Group to structure and guide anticipated clinical trials evaluating the effects of broadly neutralizing anti-SARS-CoV-2 spike protein mAb therapy in people suffering from Long COVID or PVS; expectations regarding Long COVID prevalence and burden in the U.S.; statements about the potential of mAb therapy to offer a therapeutic approach to Long COVID; expectations regarding the capability of Invivyd to explore the Long COVID space; whether pemivibart may have potential in addressing symptoms in some Long COVID patients; the potential of the SPEAR Study Group research to lay groundwork for future efficacy studies; the company's expectation to share future milestones regarding the SPEAR Study Group initiative; expectations regarding engagement between Invivyd and the FDA; the potential of PEMGARDA as a mAb for pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents who have moderate-to-severe immune compromise; the potential of VYD2311 as a novel mAb candidate; the company's devotion to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company's forward-looking statements and you should not place undue reliance on the company's forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the timing, progress and results of the SPEAR Study Group, and the company's discovery, preclinical and clinical development activities; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of the company's product candidates based on neutralizing activity in nonclinical studies; potential variability in neutralizing activity of product candidates tested in different assays, such as pseudovirus assays and authentic assays; variability of results in models and methods used to predict activity against SARS-CoV-2 variants; whether the epitope that pemivibart and VYD2311 targets remains structurally intact; whether the company's product candidates are able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; whether mAb therapy is able to offer a therapeutic approach to Long COVID; the ability to gain alignment with the applicable regulatory authorities on clinical trial designs and regulatory pathways for COVID-19 mAbs, and the timing thereof; changes in the regulatory environment; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways; future clinical trial site activation or enrollment rates; how long the EUA granted by the FDA for PEMGARDA will remain in effect and whether the EUA is revised or revoked by the FDA; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of any product candidate following regulatory authorization or approval; changes in expected or existing competition; the company's reliance on third parties; complexities of manufacturing mAb therapies; macroeconomic and political uncertainties; the company's ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading 'Risk Factors' in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each filed with the Securities and Exchange Commission (SEC), and in the company's other filings with the SEC, and in its future reports to be filed with the SEC and available at Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. Contacts: Media Relations(781) 208-1747media@ Investor Relations(781) 208-1747investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

How Close Is The World To AGI?
How Close Is The World To AGI?

Forbes

timean hour ago

  • Forbes

How Close Is The World To AGI?

Tarun Eldho Alias is a technology leader with over a decade of experience in software development and is the founder and CTO of Neem Inc. During a recent discussion with a data scientist who studies the limitations of current AI architectures and the breakthroughs needed for future general intelligence, a key question was raised that sparked a critical conversation: With the rise of AI tools like chatGPT, how close are we to artificial general intelligence? While the capabilities of LLMs are pretty impressive and there's no doubt about their commercial value, most people can agree that they aren't really intelligent. They lack a deeper understanding of the basic concepts that we take for granted, and they don't have the agency that humans have. While many experts claim that we may be closer to AGI than many people realize, are LLMs going to get us there? The Expectations Of AGI Before we can debate this, let's look at the most common traits expected by people from an AGI: • Generalization: This is the ability to learn and transfer knowledge from one domain to another and learn a variety of tasks or functions using the same model or architecture. • Reasoning: This ability solves new problems without being specifically instructed or trained on similar problems. • Awareness: This is the contextual understanding of a situation or task and the ability to maintain continuity of this understanding in both the short and long term. • Self-Supervised Learning: The model must be able to learn both knowledge and contexts without explicit labels and only through interaction with the environment and occasional prompting. • Continuous Learning: AGI must learn continuously through interaction with its environment without separate training and inference phases. Current LLMs display some of these traits, but only in limited forms. They achieve generalization and some reasoning through training on massive datasets, a process that often takes weeks or months. However, these models build statistical correlations rather than developing causal, hierarchical world models. Incorporating new information is difficult; updating an LLM with fresh data poses a challenge because of the high risk of forgetting the knowledge learned from past data. They also occasionally suffer from poor contextual awareness, particularly during long or complex conversations. In contrast, the human brain operates very differently. We interact with the world through our bodies, generating data via sensory input and motor actions. Learning happens continuously as we compare our predictions with sensory feedback, adjusting our internal models accordingly. This lifelong, embodied learning process creates a rich and evolving world model—a contextual foundation that shapes all perception and decision-making. Knowledge is built hierarchically: Simple patterns become the building blocks for increasingly complex concepts. Over time, we form new associations from past experiences, enabling us to solve problems we've never encountered before. From LLMs To AGI: Bridging The Gaps To transition from LLMs to AGI in this way, we need to overcome several major limitations and introduce fundamentally new capabilities that most current AI systems lack. These include: Training a machine learning model is essentially an optimization problem: It involves adjusting the weights between nodes in a neural network to minimize prediction errors across massive datasets. This is typically done using an algorithm called gradient descent, which requires significant computational power—especially for large language models trained on nearly the entire internet. These models often contain billions of parameters, making training both resource-intensive and time-consuming. To move toward more efficient and adaptable systems, we need new learning algorithms—potentially inspired by biological processes like Hebbian learning, where connections strengthen based on experience. Such an approach could support continuous training, enabling models to learn and make predictions at the same time, rather than in separate phases. In current neural networks, knowledge is stored in a highly distributed and overlapping way. This makes it difficult to isolate specific pathways or selectively adjust weights without disrupting previously learned information—a challenge known as catastrophic forgetting. To overcome this, we need algorithms and architectures that promote self-organizing structures and hierarchical representations. These would allow knowledge to be compartmentalized more effectively, enabling models to learn continuously without overwriting what they already know. Hierarchies also encourage the reuse of existing knowledge, which can significantly accelerate the learning of new concepts. Our brains constantly construct and maintain internal models of the world that are tailored to the context of each situation. These models help us store relevant knowledge and use it to make accurate predictions. For example, when we move through our environment, we rely on a combination of visual input, somatosensory feedback and motor activity to build a three-dimensional mental map of the space around us. This internal model is what allows us to walk to the bed in the dark without bumping into anything, or to reach for an object we've dropped without needing to see it. Planning is what allows us to apply our knowledge in pursuit of favorable outcomes. At the core of this ability is an intrinsic reward model—a mechanism that enables a system to evaluate and compare multiple possible outcomes and choose the most beneficial one. To do this effectively, the model must map sequences of events onto a timeline and simulate the sensory feedback that different actions would produce. By estimating the reward associated with each sequence, the model can identify and select the most promising course of action. As new sensory input becomes available, the plan is continuously updated to adapt to changing circumstances. Closing Thoughts While no current model possesses all of the key attributes required for AGI—and some of the necessary algorithms haven't even been developed yet—it's safe to say that we're still quite a way off from achieving true AGI. At the same time, our understanding of how the human brain accomplishes these capabilities remains incomplete. Neuroscience continues to make progress, but studying the brain in action is limited by the current tools available, making breakthroughs slow and complex. That said, progress is steady. As research advances, AGI has the potential to unlock far more capable forms of machine intelligence, powering autonomous agents, self-driving vehicles, robotics and systems that can help tackle some of humanity's most difficult problems. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store